Brief: Aadi Bioscience Posts Q1 Revenue Of $5.9 Mln

Whitehawk Therapeutics

10/05/2023 13:06

May 10 (Reuters) - Aadi Bioscience Inc  AADI.O :
    * AADI BIOSCIENCE ANNOUNCES FINANCIAL RESULTS AND
OPERATIONAL
UPDATE FOR THE FIRST QUARTER 2023 AND PROVIDES UPDATE ON
PRECISION 1 TUMOR AGNOSTIC TRIAL
    * AADI BIOSCIENCE INC - TOTAL 1Q 2023 REVENUE ON FYARRO®
SALES OF
$5.9 MILLION
    * AADI BIOSCIENCE INC - INTERIM ANALYSIS ON 40 PATIENTS WITH
APPROPRIATE FOLLOW-UP IN PRECISION 1 TRIAL EXPECTED BY END OF
2023
    * AADI BIOSCIENCE INC - CASH, CASH EQUIVALENTS AND
SHORT-TERM
INVESTMENTS AS OF MARCH 31, 2023 WERE $151.2 MILLION
    * AADI BIOSCIENCE INC - CASH, CASH EQUIVALENTS AND
SHORT-TERM
INVESTMENTS EXPECTED TO FUND OPERATIONS INTO 2025 BASED ON
CURRENT PLANS
    * AADI BIOSCIENCE INC- QTRLY LOSS PER SHARE $0.57

Source text for Eikon:  ID:nPn39cHypa 
Further company coverage:  AADI.O 

 ((Reuters.Briefs@thomsonreuters.com;))